Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities
Zhe Jiang1, Michelle S Allkanjari1, Philip E D Chung1
1Toronto General Research Institute, University Health Network, 101 College Street, Max Bell Research Centre, Suite 5R406, Toronto, ON M5G 1L7, Canada.
Abstract:
Pineoblastoma (PB) is a rare yet lethal pediatric brain cancer of the pineal gland, a small endocrine organ that secretes melatonin to regulate the circadian rhythm. For PB patients ≤5 years of age, the overall survival rate is approximately 15%; metastatic PB is incurable. Standard treatment, including surgical resection, radiation, and systemic chemotherapy, improves survival but compromises neurocognitive function. A better understanding of the disease and the generation of preclinical models may enable re-evaluation of previous clinical trials, development of precision therapeutic strategies and improve patient outcome. Over the past 5 years, PB has been recognized to include several major subtypes driven by (i) loss of microRNA processing factors DICER and DROSHA characterized by a relatively good prognosis; (ii) loss of the retinoblastoma tumor suppressor RB1; and (iii) amplification or induction of the cMYC protooncogene, with the latter two subtypes exhibiting exceedingly poor prognosis. Recently, mouse models for the major PB subtypes (RB1-, DICER1- and DROSHA-) except MYC- have been established. This progress, including better understanding of the disease, cell of origin, tumor progression, role of autophagy, and targetable vulnerabilities, holds promise for novel therapeutic strategies to combat each subtype of this lethal childhood malignancy.
Insights
Pineoblastoma (PB) is a rare pediatric brain cancer. Understanding its subtypes and developing new models offers hope for targeted therapies and improved outcomes for children with this lethal disease.
Area of Science:
- Pediatric neuro-oncology
- Cancer genomics
- Epigenetics
Background:
- Pineoblastoma (PB) is a rare, lethal pediatric brain cancer originating in the pineal gland.
- Current treatments offer limited survival rates, especially for metastatic disease, and cause significant neurocognitive deficits.
- PB comprises distinct molecular subtypes with varying prognoses, including those driven by DICER/DROSHA, RB1, and cMYC.
Purpose of the Study:
- To advance the understanding of pineoblastoma heterogeneity and progression.
- To highlight the importance of preclinical models for therapeutic development.
- To identify potential vulnerabilities for novel treatment strategies.
Main Methods:
- Review of recent advancements in pineoblastoma research, including molecular subtyping.
- Discussion of established and emerging preclinical models for PB subtypes.
- Analysis of disease mechanisms, cell of origin, and therapeutic targets.
Main Results:
- Pineoblastoma is classified into major subtypes based on genetic drivers (DICER/DROSHA loss, RB1 loss, cMYC amplification).
- Mouse models have been successfully developed for RB1-, DICER1-, and DROSHA-driven PB, but not yet for MYC-driven PB.
- Progress has been made in understanding PB biology, including tumor progression and the role of autophagy.
Conclusions:
- Subtyping and preclinical models are crucial for developing precision therapies for pineoblastoma.
- Further research into MYC-driven PB and targetable vulnerabilities is needed.
- Improved understanding holds promise for novel therapeutic strategies against this childhood malignancy.
More Related Videos
08:46A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
